Equities

Nuvation Bio Inc

NUVB:NYQ

Nuvation Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.95
  • Today's Change0.05 / 1.72%
  • Shares traded1.35m
  • 1 Year change+123.48%
  • Beta1.3826
Data delayed at least 15 minutes, as of Sep 20 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments611661765
Total Receivables, Net3.702.493.04
Total Inventory------
Prepaid expenses1.523.823.64
Other current assets, total----0
Total current assets616667772
Property, plant & equipment, net4.324.693.66
Goodwill, net------
Intangibles, net------
Long term investments0.140.140.42
Note receivable - long term------
Other long term assets0.59----
Total assets621672776
LIABILITIES
Accounts payable2.212.143.93
Accrued expenses121113
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities141317
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total2.393.9013
Total liabilities161730
SHAREHOLDERS EQUITY
Common stock948928910
Additional paid-in capital------
Retained earnings (accumulated deficit)(343)(267)(163)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.18(5.53)(1.19)
Total equity605655746
Total liabilities & shareholders' equity621672776
Total common shares outstanding219219218
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.